Septic Shock - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 74 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Septic Shock - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Septic Shock - Pipeline Review, H2 2014', provides an overview of the Septic Shock's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Septic Shock, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Septic Shock and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Septic Shock
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Septic Shock and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Septic Shock products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Septic Shock pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Septic Shock
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Septic Shock pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Septic Shock Overview 9
Therapeutics Development 10
Pipeline Products for Septic Shock - Overview 10
Pipeline Products for Septic Shock - Comparative Analysis 11
Septic Shock - Therapeutics under Development by Companies 12
Septic Shock - Therapeutics under Investigation by Universities/Institutes 14
Septic Shock - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Septic Shock - Products under Development by Companies 18
Septic Shock - Products under Investigation by Universities/Institutes 19
Septic Shock - Companies Involved in Therapeutics Development 20
Adrenomed AG 20
Compugen Ltd. 21
Ferring International Center S.A. 22
Huons Co., Ltd. 23
Lixte Biotechnology Holdings, Inc. 24
Noxxon Pharma AG 25
Orion Oyj 26
Pharmazz, Inc. 27
Spider Biotech 28
Takeda Pharmaceutical Company Limited 29
XImmune AB 30
Septic Shock - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
adrecizumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AM-12 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BTZO-2 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
centhaquine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CGEN-25068 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
HBN-1 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
HBN-3 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
HBN-4 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
HU-003 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
LB-100 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
LB-102 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
LB-1148 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
levosimendan - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
MFH-147 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
NOXD-20 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NS-4 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
R-190 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
SB-056 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
selepressin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecules to Antagonize TLR-4 for Septicemia and Septic Shock - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
SP-14 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SP-9 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Synthetic Peptides to Inhibit HSP90 for Oncology, Septic Shock, Inflammatory and Infectious Diseases - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Septic Shock - Recent Pipeline Updates 67
Septic Shock - Dormant Projects 70
Septic Shock - Discontinued Products 71
Septic Shock - Product Development Milestones 72
Featured News & Press Releases 72
Jan 02, 2013: Adrenomed Develops New Drug To Reduce Mortality From Septic Shock 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 74
Disclaimer 74

List of Tables
Number of Products under Development for Septic Shock, H2 2014 10
Number of Products under Development for Septic Shock - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Comparative Analysis by Unknown Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Septic Shock - Pipeline by Adrenomed AG, H2 2014 20
Septic Shock - Pipeline by Compugen Ltd., H2 2014 21
Septic Shock - Pipeline by Ferring International Center S.A., H2 2014 22
Septic Shock - Pipeline by Huons Co., Ltd., H2 2014 23
Septic Shock - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2014 24
Septic Shock - Pipeline by Noxxon Pharma AG, H2 2014 25
Septic Shock - Pipeline by Orion Oyj, H2 2014 26
Septic Shock - Pipeline by Pharmazz, Inc., H2 2014 27
Septic Shock - Pipeline by Spider Biotech, H2 2014 28
Septic Shock - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 29
Septic Shock - Pipeline by XImmune AB, H2 2014 30
Assessment by Monotherapy Products, H2 2014 31
Number of Products by Stage and Target, H2 2014 33
Number of Products by Stage and Mechanism of Action, H2 2014 35
Number of Products by Stage and Route of Administration, H2 2014 37
Number of Products by Stage and Molecule Type, H2 2014 39
Septic Shock Therapeutics - Recent Pipeline Updates, H2 2014 67
Septic Shock - Dormant Projects, H2 2014 70
Septic Shock - Discontinued Products, H2 2014 71